Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q3 2015 (← Previous) (Next →)

Filing Date: Nov 4, 2015

Total Value ($000): $177,613 (100.0% shares, 0.0% debt)

Holdings (10)

— Juno Therapeutics 30.5%

Value ($000) $54,098 Shares 1,329,512 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 22.9%

Value ($000) $40,639 Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Egalet 19.6%

Value ($000) $34,868 Shares 2,645,558 Est. Cost $5.69 Unrealized —

— FibroGen 10.8%

Value ($000) $19,118 Shares 872,175 Est. Cost $27.34 Unrealized —

— Nabriva Therapeutics 6.1%

Value ($000) $10,886 Shares 1,145,890 Est. Cost $9.50 Unrealized —

— ESSA Pharma 3.9%

Value ($000) $6,884 Shares 1,090,909 Est. Cost $6.31 Unrealized —

— Pieris Pharmaceuticals 2.6%

Value ($000) $4,546 Shares 2,483,949 Est. Cost $1.83 Unrealized —

— Proteon Therapeutics 2.0%

Value ($000) $3,478 Shares 250,000 Est. Cost $10.40 Unrealized —

— Dicerna Pharmaceuticals 1.0%

Value ($000) $1,835 Shares 223,457 Est. Cost $16.47 Unrealized —

— CymaBay Therapeutics 0.7%

Value ($000) $1,261 Shares 650,000 Est. Cost $1.94 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,329,512	$54,098	30.5%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,138,872	$40,639	22.9%	$38.55	—	Common Stock	699374302
—	Egalet	2,645,558	$34,868	19.6%	$5.69	—	Common Stock	28226B104
—	FibroGen	872,175	$19,118	10.8%	$27.34	—	Common Stock	31572Q808
—	Nabriva Therapeutics	1,145,890	$10,886	6.1%	$9.50	—	Sponsored ADR	62957M104
—	ESSA Pharma	1,090,909	$6,884	3.9%	$6.31	—	Common Stock	29668H104
—	Pieris Pharmaceuticals	2,483,949	$4,546	2.6%	$1.83	—	Common Stock	720795103
—	Proteon Therapeutics	250,000	$3,478	2.0%	$10.40	—	Common Stock	74371L109
—	Dicerna Pharmaceuticals	223,457	$1,835	1.0%	$16.47	—	Common Stock	253031108
—	CymaBay Therapeutics	650,000	$1,261	0.7%	$1.94	—	Common Stock	23257D103